Provided by Tiger Trade Technology Pte. Ltd.

AI Healthcare

740.54
-4.0152-0.54%
Number of Gainers:- -
Number of Losers:3
Number of Flat:1
PE:- -
High:774.48
Open:748.86
Low:738.13
Close:744.55
Volume:15.09M
Turnover:306.96M
Market Cap:23.83B
Float Cap:18.22B

Loading ...

Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal

Reuters
·
Sep 22

Tempus Extends Data Licensing Partnership with Recursion Through November 2029

Reuters
·
Sep 22

Tempus AI, Recursion Extend Data License, Amend Fee Structure

MT Newswires Live
·
Sep 21

Recursion, Tempus Expand AI and RNA Collaboration Agreements

TIPRANKS
·
Sep 21

Tempus AI, Recursion extend data license agreement, enter new license agreement

TIPRANKS
·
Sep 21

Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm

THOMSON REUTERS
·
Sep 21

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model

THOMSON REUTERS
·
Sep 21

Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Eliminates Co's Right to Terminate Agreement for Convenience - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion Pharmaceuticals - Extends Agreement Term from Five to Six Years - SEC Filing

THOMSON REUTERS
·
Sep 21

Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target

MT Newswires Live
·
Sep 21

Tempus AI EVP, Chief Legal Officer Andrew Polovin Disposes of 2,951 Common Shares for $221,325

Reuters
·
Sep 19

Tempus AI Stock (TEM) Surges 40% in a Week — Is More Upside Ahead?

TIPRANKS
·
Sep 18

Tempus AI Stock Surges as Revenue Optimism Boosts Winning Streak

Dow Jones
·
Sep 18

Recursion’s REC-7735 Trial: Early Precision Oncology Data That Could Move RXRX

TIPRANKS
·
Sep 18

Tempus AI rises 14.5%

TIPRANKS
·
Sep 18